Imaging Biometrics Limited
0.88
GBX
0.00
(0.00%)
Imaging Biometrics Limited
LSE:IBAI
(London Stock Exchange)
Recent
price
0.88
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.- Similar Companies
- Business
- Imaging Biometrics Ltd. provides advanced medical imaging software solutions and analytics to support clinical decision-making across radiology and neuroimaging disciplines; it operates as a subsidiary within IQ-AI Limited, headquartered in the United Kingdom, with principal activities centered in medical imaging software development and related regulatory consulting services. Main products and services - IB Neuro: MR DSC perfusion processing platform for quantitative cerebral perfusion assessment; integrates with standard MR imaging workflows to enable advanced neurovascular evaluation. - IB Delta Suite: Delta T1 mapping from routine MR exams to enhance tissue characterization and lesion delineation; supports multiparametric imaging workflows. - IB DCE: Dynamic contrast-enhanced imaging analytics to quantify tissue perfusion and vascular properties; applicable across oncologic and neuroimaging indications. - IB Diffusion: Diffusion-weighted imaging analytics providing whole-body insights into water diffusion for tissue characterization and tumor assessment. - IB Clinic: Unified software platform covering the IB software suite, enabling clinicians to access and manage imaging tools across modalities in a single interface. - Stone Checker: CT-based kidney stone analysis and management tools to assist non-invasive assessment and planning. - Liver Surface Nodularity: CT-based assessment aiding evaluation of liver stiffness and cirrhosis-related morphology. - IB ASL: Arterial spin labeling workflow for measuring cerebral blood flow to support stroke, dementia, and other neurological condition assessments. - IB Zero G: gadolinium-free imaging technology designed to reduce or eliminate the need for gadolinium-based contrast agents in routine imaging. - IB Nimble: Collaboration-enabled platform supporting virtual interaction among clinicians to facilitate remote review and consultation. - Related regulatory consulting and deployment services: regulatory support, deployment planning, and integration services for hospital and imaging center environments. Latest major company changes - Distribution expansion and partnerships: extended distribution arrangements with major medical imaging distributors to broaden market access for IB Neuro and Delta T1 platforms, including direct-to-customer channels and expanded geographic reach (global EF). This aligns with ongoing strategic emphasis on scalable deployment and clinician access to advanced imaging capabilities. - Corporate restructuring and leadership updates: corporate reorganizations within the IQ-AI group to streamline go-to-market and product development efforts for imaging software, reinforcing focus on radiology and neuroimaging segments. - Product and platform enhancements: introduction of updates across the IB Clinic and Delta/T1/DCE/Diffusion suites to improve interoperability, workflow integration, and data interoperability with hospital PACS and imaging informatics systems. - Expansion into new markets: targeted expansion into European and North American markets with regulatory-compliant deployments of key platforms, supported by regional partnerships and services teams. - Investment in development: ongoing investments to enhance AI-assisted imaging features, clinical validation studies, and performance benchmarking across MR and CT modalities. Additional context - Industry and business segments: medical imaging software; radiology and neuroimaging workflow solutions; regulatory consulting and deployment services. - Target markets: hospitals, academic medical centers, specialty imaging clinics, and radiology groups requiring advanced imaging analytics and non-invasive assessment tools. - Geographic operations: United States, United Kingdom, Switzerland, European Union markets, and other regions through distributors and partners; listed as operating primarily from the UK with global reach via IQ-AI group. - Founding year and headquarters: established in the United States in the late 2000s; corporate governance and parent linkage to IQ-AI Limited, with headquarters associated with IQ-AI’s holding structure in the UK/Channel Islands framework. - Subsidiaries and parent relationships: Imaging Biometrics, LLC (US-based software subsidiary) and Stone Checker Software Limited (kidney stone analysis solutions) under IQ-AI Limited; Imaging Biometrics operates as the imaging software arm within the group. Notes - The description emphasizes the company’s core imaging software portfolio, cross-border deployment capabilities, and recent strategic moves toward broader distribution, platform enhancements, and geographic expansion, while identifying its relationship to IQ-AI Limited and its parent/subsidiary framework.